Initial therapy of patients with Wilson's disease with tetrathiomolybdate.

No abstract is available for this paper.

• Publication year

  1991

• Venue

  Archives of Neurology

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1001/ARCHNEUR.1991.00530130050019PMID 1986725
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Wilson's disease: an update, with emphasis on new approaches to treatment.

  1989cited by this paper
• Treatment of Wilson's Disease

  1987cited by this paper
• Worsening of neurologic syndrome in patients with Wilson's disease with initial penicillamine therapy.

  1987cited by this paper
• Treatment of Wilson's disease with zinc. I. Oral zinc therapy regimens

  1987cited by this paper
• Huntington's disease in Venezuela

  1986cited by this paper
• Oral zinc therapy for Wilson's disease.

  1983cited by this paper
• Oral zinc therapy for Wilson's disease.

  1983cited by this paper
• Syntheses and characterization of ammonium and tetraalkylammonium thiomolybdates and thiotungstates

  1983cited by this paper
• Copper metabolism in rats given di- or trithiomolybdates.

  1982cited by this paper
• An investigation of the effects of intravenous administration of thiomolybdate on copper metabolism in chronic Cu-poisoned sheep

  1981cited by this paper
• Copper and molybdenum absorption by rats given ammonium tetrathiomolybdate.

  1981cited by this paper
• Effects of molybdate, sulfide, and tetrathiomolybdate on copper metabolism in rats.

  1981cited by this paper
• Motor Speech Disorders

  1975cited by this paper

• Mechanisms, therapeutic uses, and developmental perspectives of redox-active thiomolybdates

  2025cites this paper
• TDMQ20 as A Drug Candidate for Wilson’s Disease: Comparison with D-Penicillamine, Trientine, and Tetrathiomolybdate In Vitro and In Mice

  2025influential citation
• Bis(4-aminopyridinium) and bis(2-amino-6-methylpyridinium) cations stabilised by [MS4]2− anions: Synthesis, crystal structures, Hirshfeld surface analysis and sulfur transfer reactions

  2025cites this paper
• Comprehensive Pharmacological Management of Wilson’s Disease: Mechanisms, Clinical Strategies, and Emerging Therapeutic Innovations

  2025cites this paper
• Pitfalls in the Diagnosis of Wilson Disease

  2025cites this paper
• Hexyltrimethylammonium ion enhances potential copper-chelating properties of ammonium thiomolybdate in an in vivo zebrafish model.

  2024cites this paper
• Antioxidative effects of molybdenum and its association with reduced prevalence of hyperuricemia in the adult population

  2024cites this paper
• Superoxide signal orchestrates tetrathiomolybdate-induced longevity via ARGK-1 in Caenorhabditis elegans.

  2024cites this paper
• Cuproptosis: A Copper-Mediated Programmed Cell Death.

  2024cites this paper
• Polymeric Copper Chelator for Long-term Inhibition of Breast Cancer Proliferation and Lung Metastasis

  2023cites this paper
• Influence of Silver Nanoparticles on the Growth of Ascitic and Solid Ehrlich Adenocarcinoma: Focus on Copper Metabolism

  2023cites this paper
• Effects of tetrathiomolybdate on copper metabolism in healthy volunteers and in patients with Wilson disease.

  2023cites this paper
• Exploring the potential of Trientine Tetrahydrochloride in the treatment of Wilson disease

  2023cites this paper
• Cuproptosis: A novel therapeutic target for overcoming cancer drug resistance.

  2023cites this paper
• Modulation of Reactive Oxygen Species to Overcome 5-Fluorouracil Resistance

  2022cites this paper
• In Vitro Characterization of a Threonine-Ligated Molybdenyl-Sulfide Cluster as a Putative Cyanide Poisoning Antidote; Intracellular Distribution, Effects on Organic Osmolyte Homeostasis, and Induction of Cell Death.

  2022cites this paper
• Tetrathiomolybdate Treatment Attenuates Bleomycin-Induced Angiogenesis and Lung Pathology in a Sheep Model of Pulmonary Fibrosis

  2021cites this paper
• Redox-Active Metal Ions and Amyloid-Degrading Enzymes in Alzheimer’s Disease

  2021cites this paper
• Wilson’s Disease

  2021cites this paper
• The Effects of Redox-Active Metal Ions and Amyloid-Degrading Enzymes on the Pathology of Alzheimer's Disease

  2021cites this paper
• Analyzing the Therapeutic Efficacy of Bis-Choline-Tetrathiomolybdate in the Atp7b−/− Copper Overload Mouse Model

  2021cites this paper
• Current Biomedical Use of Copper Chelation Therapy

  2020cites this paper
• Synthesis, characterization and biological evaluation of octyltrimethylammonium tetrathiotungstate

  2020cites this paper
• Ammonium tetrathiomolybdate in the decoppering phase treatment of Wilson's disease with neurological symptoms: A case series

  2020cites this paper
• Copper Dyshomeostasis in Neurodegenerative Diseases—Therapeutic Implications

  2020cites this paper
• Diverse biological roles of the tetrathiomolybdate anion

  2020cites this paper
• Synthesis, characterization and biological evaluation of octyltrimethylammonium tetrathiotungstate

  2020cites this paper
• Copper

  2020cites this paper
• History of Wilson Disease

  2019cites this paper
• Wilson's Disease: Clinical Practice Guidelines of the Indian National Association for Study of the Liver, the Indian Society of Pediatric Gastroenterology, Hepatology and Nutrition, and the Movement Disorders Society of India.

  2019cites this paper
• Comparative effectiveness of common therapies for Wilson disease: A systematic review and meta‐analysis of controlled studies

  2019cites this paper
• Ammonium tetrathiomolybdate treatment of copper‐associated hepatopathy in dogs

  2019influential citation
• WTX101 – an investigational drug for the treatment of Wilson disease

  2018cites this paper
• Tetrathiomolybdate, a copper chelator inhibited imiquimod-induced skin inflammation in mice.

  2018cites this paper
• Advances in Treatment of Wilson Disease

  2018cites this paper
• Kanatzidis and Coucouvanis , “ Structure of Bis ( tetraethy lammonium ) tetrathiomolybdte ( VI ) , 2 CHN " MoS

  2017cites this paper
• Mitochondrial copper overload in a rat model for Wilson disease is paralleled by upregulated COX17 and can be restored using the bacterial peptide methanobactin

  2017cites this paper
• Disorders in Hepatic Copper Secretion: Wilson's Disease and Pleomorphic Syndromes

  2017cites this paper
• Molybdenum Metallopharmaceuticals Candidate Compounds - The "Renaissance" of Molybdenum Metallodrugs?

  2016cites this paper
• Influencing the Tumor Microenvironment: A Phase II Study of Copper Depletion Using Tetrathiomolybdate in Patients with Breast Cancer at High Risk for Recurrence and in Preclinical Models of Lung Metastases

  2016cites this paper
• Chelating Therapy in Metal Storage Diseases

  2016cites this paper
• Copper suppression as cancer therapy: the rationale for copper chelating agents in BRAFV600 mutated melanoma.

  2016cites this paper
• Wilson's disease: A review of what we have learned.

  2015cites this paper
• The Modern Treatment of Wilson's Disease

  2015cites this paper
• The role of copper ions in pathophysiology and fluorescent sensors for the detection thereof.

  2015cites this paper
• Pharmacologic evaluation of ammonium tetrathiomolybdate after intravenous and oral administration to healthy dogs.

  2015cites this paper
• Using canine osteosarcoma as a model to assess efficacy of novel therapies: can old dogs teach us new tricks?

  2014influential citation
• Neurologic Wilson’s Disease and its Management - An Update

  2014cites this paper
• Copper induces – and copper chelation by tetrathiomolybdate inhibits – endothelial activation in vitro

  2014cites this paper
• LAPAROSCOPIC EVALUATION OF ENDOMETRIOSIS

  2014cites this paper
• Neurologic Wilson ’ s Disease and its Management-An Update

  2014cites this paper
• Copper chelators: chemical properties and bio-medical applications.

  2014influential citation
• A review and current perspective on Wilson disease.

  2013cites this paper
• Tetrathiomolybdate-associated copper depletion decreases circulating endothelial progenitor cells in women with breast cancer at high risk of relapse.

  2013cites this paper
• Efficacy and safety of oral chelators in treatment of patients with Wilson disease.

  2013cites this paper
• Bioavailable copper modulates oxidative phosphorylation and growth of tumors

  2013cites this paper
• Low-Glucose Conditions of Tumor Microenvironment Enhance Cytotoxicity of Tetrathiomolybdate to Neuroblastoma Cells

  2013cites this paper
• Worsening of Wilson Disease following Penicillamine Therapy

  2013cites this paper
• 3.35 – Chelation Therapy

  2013cites this paper
• Chelating Agents as Tools for the Treatment of Metal Overload

  2013cites this paper
• Evolving Perspectives in Wilson Disease: Diagnosis, Treatment and Monitoring

  2012cites this paper
• Evaluación de la eficacia y seguridad del tratamiento con tetratiomolibdato de amonio en la enfermedad de Wilson con afectación neurológica

  2012cites this paper
• Metals in the causation and treatment of Wilson’s disease and Alzheimer’s disease, and copper lowering therapy in medicine

  2012cites this paper
• Good response with zinc acetate monotherapy in an adolescent affected by severe Wilson disease.

  2012cites this paper
• Copper-dependent cytotoxicity of 8-hydroxyquinoline derivatives correlates with their hydrophobicity and does not require caspase activation.

  2012cites this paper
• Wilson's disease.

  2011cites this paper
• Wilson Disease: Pathogenesis and Clinical Considerations in Diagnosis and Treatment

  2011cites this paper
• Wilson Disease Watch

  2011cites this paper
• Copper chelation by tetrathiomolybdate inhibits lipopolysaccharide-induced inflammatory responses in vivo.

  2011cites this paper
• Tetrathiomolybdate Inhibits Copper Trafficking Proteins Through Metal Cluster Formation

  2010cites this paper
• Copper and Lead

  2010cites this paper
• Development of a new bimodal imaging methodology: a combination of fluorescence microscopy and high‐resolution secondary ion mass spectrometry

  2010cites this paper
• Chelation therapies: a chemical and biochemical perspective.

  2010cites this paper
• On the reaction mechanism of MoS42− with nitric oxide

  2010cites this paper
• In situ imaging of metals in cells and tissues.

  2009cites this paper
• Copper chelation in cancer therapy using tetrathiomolybdate: an evolving paradigm

  2009cites this paper
• The use of copper-lowering therapy with tetrathiomolybdate in medicine

  2009influential citation
• Zinc and tetrathiomolybdate for the treatment of Wilson's disease and the potential efficacy of anticopper therapy in a wide variety of diseases.

  2009cites this paper
• Neutropenia caused by copper deficiency: possible mechanisms of action.

  2009cites this paper
• Copper chelation in cancer therapy using tetrathiomolybdate: an evolving paradigm.

  2009cites this paper
• Reduced expression of ATP7B affected by Wilson disease–causing mutations is rescued by pharmacological folding chaperones 4‐phenylbutyrate and curcumin

  2009cites this paper
• Tracing copper-thiomolybdate complexes in a prospective treatment for Wilson's disease.

  2009cites this paper
• Medicinal inorganic chemistry approaches to passivation and removal of aberrant metal ions in disease.

  2009cites this paper
• The conquest of Wilson's disease.

  2009influential citation
• Systematic review: clinical efficacy of chelator agents and zinc in the initial treatment of Wilson disease

  2009cites this paper
• Structure-function relationships in cellular copper control

  2009cites this paper
• Treatment of Wilson's disease with tetrathiomolybdate: V. Control of free copper by tetrathiomolybdate and a comparison with trientine.

  2009cites this paper
• Improvement in Dissolution of Liver Fibrosis in an Animal Model by Tetrathiomolybdate

  2009cites this paper
• Drug development for orphan diseases in the context of personalized medicine.

  2009cites this paper
• New developments in the regulation of intestinal copper absorption.

  2009cites this paper
• Tetrathiomolybdate, a copper chelator for the treatment of Wilson disease, pulmonary fibrosis and other indications.

  2008cites this paper
• Efficacy of tetrathiomolybdate in a mouse model of multiple sclerosis.

  2008cites this paper
• Tetrathiomolybdate Is Partially Protective Against Hyperglycemia in Rodent Models of Diabetes

  2008cites this paper
• Progress in Neurotherapeutics and Neuropsychopharmacology: Tetrathiomolybdate versus Trientine in the Initial Treatment of Neurologic Wilson's Disease

  2008cites this paper
• Tetrathiomolybdate Protects against Bile Duct Ligation-Induced Cholestatic Liver Injury and Fibrosis

  2008cites this paper
• Molecular pathogenesis of Wilson and Menkes disease: correlation of mutations with molecular defects and disease phenotypes

  2007cites this paper
• Antitumor and antiinflammatory effects of tetrathiotungstate in comparison with tetrathiomolybdate.

  2007cites this paper
• Phase II Trial of Copper Depletion with Tetrathiomolybdate as an Antiangiogenesis Strategy in Patients with Hormone-Refractory Prostate Cancer

  2007cites this paper
• Novel therapeutic approaches to the treatment of Wilson’s disease

  2006cites this paper
• The use of tetrathiomolybdate in treating fibrotic, inflammatory, and autoimmune diseases, including the non-obese diabetic mouse model.

  2006cites this paper